Abstract |
Twenty-five adult patients with previously untreated acute non- lymphocytic leukemia ( ANLL) were treated with mitoxantrone (Mto) 12 mg/m2 daily by 30 minutes intravenous (IV) infusion for 3 days and cytosine arabinoside ( Ara-C) 200 mg/m2 daily by continuous infusion for 7 days, as an induction therapy. After complete remission (CR) was observed, they were given two more courses of consolidation therapy which was as Mto 12 mg/m2 daily by 30 minutes IV infusion for one day, and Ara-C 200 mg/m2 daily by 30 minutes IV infusion for 5 days. CR was obtained in 18 of 25 patients (72%). Median remission duration was 294 days and length of survival was 366 days. 11 patients (44%) are still in remission. Myelosupression developed in all patients following induction therapy, but it was not observed after consolidation therapies. Non-hematological side-effects consisted of nausea, vomiting, alopecia, stomatitis, and transient elevation in liver enzymes. Our therapeutic responses are similar to those obtained by others.
|
Authors | I Osman, U Akin, A Ismet, B Meral, A Hamdi, K Haluk |
Journal | Haematologia
(Haematologia (Budap))
Vol. 27
Issue 2
Pg. 93-7
( 1996)
ISSN: 0017-6559 [Print] Netherlands |
PMID | 14651226
(Publication Type: Clinical Trial, Journal Article)
|
Chemical References |
|
Topics |
- Adolescent
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects, therapeutic use)
- Bone Marrow Diseases
(chemically induced)
- Cytarabine
(administration & dosage, adverse effects)
- Disease-Free Survival
- Female
- Gastrointestinal Diseases
(chemically induced)
- Humans
- Leukemia, Myeloid, Acute
(drug therapy)
- Male
- Middle Aged
- Mitoxantrone
(administration & dosage, adverse effects)
- Remission Induction
- Treatment Outcome
|